A new Covid variant, NB.1.8.1, raises alarms for its potential to spread rapidly and evade antibodies. Meanwhile, the FDA approves a long-lasting HIV injection, and concerns about public safety arise with ICE's rule changes.
Explore groundbreaking health trends from exosome treatments and HIV prevention injections to new obesity pills and brain implants. What do experts really think? Dive into the latest in health innovation and skepticism.
A new COVID-19 variant known as 'Nimbus' is causing concern due to its painful sore throat symptom, dubbed 'razor blade throat.' While cases rise, experts assure the public that current vaccines should remain effective.
From the shocking endorsement of bleach solutions by RFK Jr. to the discovery of how axolotls regenerate limbs, this article dives into the latest news that is stirring both scientific curiosity and controversy. Discover the implications of these findings!
A new COVID-19 variant, NB.1.8.1, dubbed 'razor blade throat,' is causing severe sore throats in some cases. Experts say it’s more transmissible but not more severe than previous variants.
A new COVID-19 variant known as 'razor blade throat' is causing concern due to painful sore throats. However, experts say it poses a low risk. Learn more about its spread and symptoms.
A new COVID-19 variant nicknamed 'razor blade throat' is causing concern due to its painful sore throat symptom. However, experts say it's not more severe than previous variants. Here's what you need to know.
The NB.1.8.1 variant of COVID-19 is rapidly spreading in the U.S., now accounting for 37% of cases. Experts warn it may lead to a summer surge, although its severity remains uncertain.
Experts are raising alarms about the new Covid variant 'Nimbus', which is spreading rapidly across the US. With symptoms like 'razor blade throat', this variant may be the most infectious yet. Learn what it means for public health and vaccine effectiveness.
In a groundbreaking move, the FDA has approved Moderna's lower-dose Covid-19 vaccine for older adults and at-risk individuals. Get ready for a new option this fall as Moderna targets the LP.8.1 variant!
